Premium
Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records
Author(s) -
Tornio Aleksi,
Flynn Rob,
Morant Steve,
Velten Elena,
Palmer Colin N. A.,
MacDonald Thomas M.,
Doney Alex S. F.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.780
Subject(s) - clopidogrel , cyp2c19 , medicine , stroke (engine) , pharmacogenetics , hazard ratio , confidence interval , medical prescription , population , clinical endpoint , cardiology , emergency medicine , pharmacology , clinical trial , myocardial infarction , cytochrome p450 , biology , genetics , gene , genotype , mechanical engineering , environmental health , metabolism , engineering
Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 ( CYP ) 2C19 , however, few studies have considered patients who have a stroke. We used electronic medical records (EMRs) linked to a bioresource to examine real‐world implications of clopidogrel pharmacogenetics in stroke. Patients hospitalized for any arterial thrombo‐occlusive (ATO) event who subsequently redeemed clopidogrel prescriptions in the community were entered into the study ( n = 651). During 24‐month follow‐up, the primary endpoint of recurrent ATO or death occurred in 299 patients (46%). CYP2C19*2 loss‐of‐function allele carriers had an increased risk (hazard ratio (HR) = 1.29; 95% confidence interval (CI) = 1.04–1.59; P = 0.019). In the ischemic stroke subgroup ( n = 94), the estimate of risk was greater (HR = 2.23; 95% CI = 1.17–4.24; P = 0.015), which was further supported by a meta‐analysis of available studies. In conclusion, we have demonstrated the clinical impact of CYP2C19*2 on clopidogrel efficacy using a purely EMR approach. This suggests that the risk in the ischemic stroke population may be particularly high.